Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Active not recruiting 3Recruiting 1

Sponsor Class

INDUSTRY 33OTHER 30NETWORK 4OTHER_GOV 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4Adenocarcinoma 1

Interventions

Specimen Handling 68Magnetic Resonance Spectroscopy 53Cyclophosphamide 45Vincristine 38Radiotherapy 31Radiation 31Cisplatin 31Carboplatin 30Dexamethasone 27Etoposide 26Doxorubicin 25Biopsy 25daratumumab 17Radiotherapy, Intensity-Modulated 17Prednisone 17Platinum 16Paclitaxel 16Irinotecan 16Cytarabine 16durvalumab 15Gemcitabine 151,2-diaminocyclohexaneplatinum II citrate 15Observation 14Methotrexate 14Leucovorin 14Docetaxel 14Lenalidomide 13X-Rays 12Watchful Waiting 12Rituximab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NETWORK × darolutamide × 1 year × Clear all
NCT04484818 2026-05-05

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
27 enrolled
Genitourinary

Prostatic Neoplasms

NCT06592924 2026-04-14

TRIPLE-SWITCH

Canadian Cancer Trials Group

Phase 3 Recruiting
830 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT02972060 2025-09-19

ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Active not recruiting
61 enrolled
Genitourinary

Prostatic Neoplasms

NCT03385655 2025-08-21

Prostate Cancer Biomarker Enrichment and Treatment Selection

Canadian Cancer Trials Group

Phase 2 Active not recruiting
200 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡